Showing 1 - 4 of 4
Persistent link: https://www.econbiz.de/10008784027
Persistent link: https://www.econbiz.de/10005238597
Persistent link: https://www.econbiz.de/10005238768
Regulatory approval of new therapies often depends on demonstrating prolonged survival. Particularly when these survival benefits are modest, consideration of therapeutic benefits to patient-reported outcomes (PROs) may add value to the traditional biomedical clinical trial endpoints. We extend...
Persistent link: https://www.econbiz.de/10010605471